Concepedia

Reginald B. Ewesuedo

RB

13

Publications

585

Citations

12

H-Index

1997

Active since

Affiliations

Pfizer (United States)(Current)

University of Chicago

Cancer Research Center

Stanford University

Florida Cancer Care

Reginald B. Ewesuedo is an author at Pfizer (United States) specializing in pharmacology, cancer therapeutics, and oncology.

ORCID

Top concepts

Publications per year

1997–2022

13

Publications

13

Phase I Trial of Carmustine Plus O6-Benzylguanine for Patients With Recurrent or Progressive Malignant Glioma

Henry S. Friedman, James M. Pluda, Jennifer A. Quinn et al. · Journal of Clinical Oncology · 2000 · 113 citations

Phase I clinical and pharmacological study of O6-benzylguanine followed by carmustine in patients with advanced cancer.

Richard L. Schilsky, M. Eileen Dolan, Donna Bertucci et al. · PubMed · 2000 · 106 citations

, , +14

Topoisomerase I Inhibitors

Reginald B. Ewesuedo, Mark J. Ratain · The Oncologist · 1997 · 91 citations · Full text

PF-05280014 (a trastuzumab biosimilar) plus paclitaxel compared with reference trastuzumab plus paclitaxel for HER2-positive metastatic breast cancer: a randomised, double-blind study

Mark D. Pegram, Igor Bondarenko, Marina Moreira Costa Zorzetto et al. · British Journal of Cancer · 2018 · 59 citations · Full text

A phase I pharmacokinetics study comparing PF-06439535 (a potential biosimilar) with bevacizumab in healthy male volunteers

Beverly Knight, Danielle Rassam, Shanmei Liao et al. · Cancer Chemotherapy and Pharmacology · 2016 · 50 citations · Full text

Rows per page

1–5 of 13